Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Ann Silk, MD
CONTACT
Ann Silk, MD
CONTACT
Lead
Dana-Farber Cancer Institute
With
This is a Phase IV, multi-site, multi-cohort, open-label clinical trial investigating the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). Checkpoint Therapeutics is supporting this research study by providing the study drug, cosibelimab. Participants will be enrolled into one of two study groups: Group A or Group B. Cosibelimab is FDA-approved for the treatment of advanced cutaneous squamous cell carcinoma The research study procedures include screening for eligibility, in-clinic visits, blood tests, urine tests, Computerized Tomography (CT) scans, or Positron Emission (PET) scans, electrocardiograms (ECGs), Tumor biopsies and aspirations. It is expected that about 80 people will take part in this research study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
